Brigham and Women's Hosp. Novel Adenoviral Vector Prophylactic HIV Vaccine Non-Network CRS is a clinical research site located in Boston, Massachusetts, United States 02115-6110.
Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.
Brigham and Women's Hosp. Novel Adenoviral Vector Prophylactic HIV Vaccine Non-Network CRS has participated in 3 clinical trials.
Therapeutic areas: HIV Infections.
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID).
Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Brigham and Women's Hosp. Novel Adenoviral Vector Prophylactic HIV Vaccine Non-Network CRS has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Brigham and Women's Hosp. Novel Adenoviral Vector Prophylactic HIV Vaccine Non-Network CRS has 3 clinical trials on record. Their work covers HIV Infections.
Brigham and Women's Hosp. Novel Adenoviral Vector Prophylactic HIV Vaccine Non-Network CRS has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.